List view / Grid view
NICE has approved palbociclib through the Cancer Drugs Fund, meaning that women with advanced breast cancer who have already received hormone therapy will now be eligible for palbociclib on the NHS.
A document from the DHSC has reportedly advised NHS doctors to ration certain medicines after outlining dozens of drugs that are in shortage, as published in a report.
Following guidance from the drugs advisory body NICE, two cannabis-based medications have been approved for treatment by the NHS in England.
The DHSC and three companies have signed contracts worth £25 million to ensure that essential medicines can be supplied to the UK in 24 to 48 hours.
The UK Competition and Markets Authority has alleged that Aspen paid two other pharmaceutical companies to ensure they were the only supplier of a drug to the NHS.
Lanadelumab, a preventive treatment for hereditary angioedema, has been recommended as a cost-effective use of NHS resources.
The seven centres will aid disease research and clinical development, improving access to patient data for studies.
The Kymriah (tisagenlecleucel) treatment has received a positive appraisal from the Scottish Medicines Consortium, after EMA approval last year.
The voretigene neparvovec gene therapy treatment has been highlighted in draft guidance by NICE for availability on the NHS.
An NHS-wide plan to use more generic and biologic products has reportedly saved the healthcare provider £700 million since 2016.
A statement from 11 health union leaders highlights the possibility of severe drug shortages if the UK leaves the EU without a deal.
The CMA alleges that Aspen broke competition law, prompting the drug supplier to offer a payment and other compensations to the NHS.
The NICE and NHS have announced their draft recommendations for the prescribed use of cannabis-based treatments.
The NHS is set to launch a new payment method for antibiotic development to incentivise pharmaceutical companies.
Seven medications have been suggested for removal from prescriptions by the NHS after a public consultation.
